Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Hypertension ; 50(5): 919-25, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17846350

ABSTRACT

Mineralocorticoid receptor blockade improves mortality early after myocardial infarction (MI). This study investigated the vascular effects of mineralocorticoid receptor blockade in the early phase postinfarction in rats. Starting immediately after coronary ligation, male Wistar rats were treated with placebo or eplerenone (100 mg/kg/d). After 7 days, hemodynamic assessment was performed and endothelial function was determined. Maximum acetylcholine-induced relaxation was significantly attenuated in aortic rings from rats with heart failure after MI, and ameliorated by eplerenone treatment. Endothelium-independent relaxation by DEA-NONOate was similar among the groups. Endothelial NO synthase phosphorylation was reduced in the aorta of MI rats and restored by eplerenone therapy. Angiotensin I-induced vasoconstriction as well as angiotensin-converting enzyme protein levels were enhanced in aortas from MI placebo rats, and reduced by mineralocorticoid receptor inhibition. Aortic reactive oxygen species formation as well as the expression of the NAD(P)H oxidase subunit p22(phox) were increased after MI and normalized in eplerenone treated rats. In conclusion, mineralocorticoid receptor antagonism improved endothelial dysfunction in the early phase post-MI. Underlying mechanisms involve inhibition of vascular angiotensin-converting enzyme upregulation and improvement of endothelial NO synthase-derived NO bioavailability.


Subject(s)
Mineralocorticoid Receptor Antagonists , Myocardial Infarction/drug therapy , Myocardial Infarction/physiopathology , Oxidative Stress/drug effects , Spironolactone/analogs & derivatives , Vasomotor System/drug effects , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/physiopathology , Disease Models, Animal , Dose-Response Relationship, Drug , Eplerenone , Male , Mineralocorticoid Receptor Antagonists/therapeutic use , NADPH Oxidases/metabolism , Organ Culture Techniques , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Spironolactone/therapeutic use , Time Factors , Vasodilation/drug effects , Vasodilator Agents/pharmacology , Vasomotor System/physiopathology
2.
Arterioscler Thromb Vasc Biol ; 27(1): 55-62, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17082482

ABSTRACT

OBJECTIVE: The chemokine fractalkine activates platelets and induces leukocyte adhesion to the endothelium. Expression of fractalkine and its receptor, CX3CR1, is elevated in coronary artery disease. We assessed the effects of fractalkine on vascular function in isolated rat aorta. METHODS AND RESULTS: CX3CR1 expression was demonstrated in rat aortic endothelial and smooth muscle cells by immunohistochemistry, Western blot, and polymerase chain reaction (PCR). Fractalkine (up to 1 microg/mL) did not directly induce contractile or relaxant responses when applied to rat aortic rings in organ baths. Short-term incubation with fractalkine (1 microg/mL) for 5 minutes did not affect vascular reactivity. Pretreatment of isolated rat aortic rings with fractalkine for 2 hours impaired acetylcholine-induced nitric oxide (NO)-mediated relaxation after preconstriction with phenylephrine in a concentration-dependent manner. The concentration response to the NO donor DEA-NONOate was significantly shifted to the right. The radical scavenger tiron normalized the attenuated acetylcholine-induced relaxation after fractalkine incubation. Aortic superoxide formation was enhanced by fractalkine, which was inhibited by diphenyleneiodonium but not by inhibitors of xanthine oxidase or NO synthase. CONCLUSIONS: In addition to its role as a chemokine and adhesion molecule, fractalkine induces vascular dysfunction by stimulating vascular reactive oxygen species resulting in reduced NO bioavailability.


Subject(s)
Chemokines, CX3C/physiology , Endothelium, Vascular/physiopathology , Membrane Proteins/physiology , Muscle, Smooth, Vascular/physiopathology , Superoxides/metabolism , Acetylcholine/pharmacology , Animals , CX3C Chemokine Receptor 1 , Cells, Cultured , Chemokine CX3CL1 , Endothelium, Vascular/metabolism , Homeostasis/physiology , Humans , Male , Muscle, Smooth, Vascular/metabolism , NADPH Oxidases/genetics , NADPH Oxidases/metabolism , Nitric Oxide/metabolism , Rats , Rats, Wistar , Receptors, Chemokine/genetics , Receptors, Chemokine/metabolism , Vasodilator Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...